J Korean Neurol Assoc.  1989 Dec;7(2):252-257.

A Study of Antiaggregatory Effect of Antiplatelet Agents by Platelet Aggregation Test

• Lee WY
• Roh JK
• Cho HI
• Lee SB
• Myung HJ

Abstract

We performed platelet aggregation test in sixty three patients (54 ; cerebral infarction, 9 ; transient ischemic attack) who were randomly treated with aspirin 300mg/day or dipyridamole 150mg/day, singlely or in combination or ticlopidine 500mg/day to evaluate the inhibitory effect of commonly used antiplatelet agents on platelet aggregation. All patients had normal baseline platelet aggregation responses to 4 stimuli ; adenosine diphosphate, epinephrine, collagen and ristocetin. Our study showed no inhibitory response to platelet aggregation at least 7 days after antiplatelet administration in 41.1% (14/34) of aspirin group, 9.5% (2/21) of ticlopidine group, and 100% (8/8) of dipyridamole group. In all of the 9 patients with normal aggregation response to aspirin therapy, platelet aggregation test was converted to inhibitory response by ticlopidine. In contrast, in all of the 2 patients with normal aggregation response to ticlopidine therapy, platelet aggregation test was converted to inhibitory response by aspirin. This study confirms previous findings of platelet inhibition by ticlopidine and aspirin in patients with ischemic cerebrovascular disease. And these results suggest that dipyridamole do not inhibit platelet aggregation in vivo.

MeSH Terms

Adenosine Diphosphate
Aspirin
Blood Platelets*
Cerebral Infarction
Collagen
Dipyridamole
Epinephrine
Humans
Infarction
Platelet Aggregation Inhibitors*
Platelet Aggregation*
Ristocetin
Ticlopidine
Adenosine Diphosphate
Aspirin
Collagen
Dipyridamole
Epinephrine
Platelet Aggregation Inhibitors
Ristocetin
Ticlopidine